Alnylam Pharmaceuticals (ALNY) reported preliminary full-year 2023 net product revenues of $1.24 billion, representing 39$1.83 billion. The company’s net product revenues comprise sales of its four marketed products, such as Onpattro, Amvuttra, Givlaari and Oxlumo. In 2023, preliminary global net product revenues for Onpattro and Amvuttra were approximately $355 million and$558 million, respectively, representing a ...